EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Juan Carlos Hernández-Boluda iD, Vipul Sheth, Simona Iacobelli, Linda Koster, Nicolaus Kröger, Patrizia Chiusolo iD, Thomas Schroeder, Marie Robin iD, Massimiliano Gambella, Didier Blaise, Henrik Sengeloev iD, Jakob Passweg und 13 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.70049 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Juan Carlos Hernández-Boluda und 24 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Clínico Universitario, INCLIVA, University of Valencia, Valencia, Spain. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Hematopoietic Stem Cell Transplantation, Tissue Donors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Selecting the optimal donor is crucial for optimizing results of allogeneic hematopoietic cell transplantation (allo‐HCT). We analyzed outcomes based on donor type in 2809 myelofibrosis (MF) patients undergoing first allo‐HCT between 2015 and 2021 at EBMT centers. Study outcomes included overall survival (OS), progression‐free survival (PFS), relapse, non‐relapse mortality (NRM), engraftment, and graft‐versus‐host disease (GvHD). Four groups were compared: matched sibling donor (MSD, n = 742), matched unrelated donor (MUD, n = 1401), mismatched unrelated donor (MMUD, n = 379) and haploidentical donor (HD, n = 287). After a median follow‐up of 33.5 months, 3‐year OS rates were 65.8%, 61.5%, 53.2%, and 57.7% for MSD, MUD, MMUD, and HD, respectively. Multivariable analyses (MSD as reference) showed that donor type significantly correlated with OS (HR: 1.63 for MMUD, HR: 1.42 for HD), PFS (HR: 1.38 for MMUD), NRM (HR: 1.73 for MMUD, HR: 1.47 for HD), engraftment (HR: 0.72 for MMUD, HR: 0.40 for HD), grade 2–4 acute GvHD (HR: 1.53 for MUD, HR: 1.69 for MMUD, HR: 1.49 for HD), and extensive chronic GvHD (HR: 0.77 for MUD, HR: 0.65 for HD). Donor type was not associated with relapse risk. In patients over 60 years, correlations between donor type and outcomes were consistent with those in the overall study population. In summary, with current practices, MF patients receiving MSD or MUD grafts achieve comparable outcomes. In contrast, MMUD and HD transplants have worse OS due to increased NRM. MMUD transplants have a higher risk of GvHD than HD transplants, but this difference seems to disappear with post‐transplant cyclophosphamide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisHematopoietic Stem Cell TransplantationTissue DonorsHumansMiddle AgedFemaleMaleGraft vs Host DiseaseAdultAgedTransplantation, HomologousUnrelated DonorsTreatment OutcomeSiblingsSurvival RateRetrospective Studies

Stichwörter der Autor:innen

donor typemyelofibrosisoutcometransplantation

Autor:innen und Institutionen

  • Hospital Clínico Universitario, INCLIVA, University of Valencia, Valencia, Spain.
  • Rajiv Gandhi Cancer Research Institute and Research Center, RGCIRC, New Delhi, India.
  • Department of Public Health and Infectious Diseases, University of Rome Sapienza, Rome, Italy.
  • EBMT Leiden Study Unit, Leiden, the Netherlands.
  • University Hospital Eppendorf, Hamburg, Germany.
  • Ematologia e Trapianto-Dipartimento di Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.

ORCID-Profile: Juan Carlos Hernández-Boluda, Patrizia Chiusolo, Marie Robin, Henrik Sengeloev, Joanna Drozd-Sokolowska, Nicola Polverelli, Tomasz Czerw

Zitieren

APA

Hernández-Boluda, J. C., Sheth, V., Iacobelli, S., Koster, L., Kröger, N., Chiusolo, P., Schroeder, T., Robin, M., Gambella, M., Blaise, D., Sengeloev, H., Passweg, J., Stelljes, M., Zeiser, R., Yakoub-Agha, I., Clark, A., Salmenniemi, U., Galieni, P., Rabisch, W., …, & McLornan, D. P. (2025). Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT. American Journal of Hematology. https://doi.org/10.1002/ajh.70049

Vancouver

Hernández-Boluda JC, Sheth V, Iacobelli S, Koster L, Kröger N, Chiusolo P, et al. Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT. American Journal of Hematology. 2025. doi:10.1002/ajh.70049

BibTeX
@article{HernndezBoluda2025,
  author = {Hernández-Boluda, Juan Carlos and Sheth, Vipul and Iacobelli, Simona and Koster, Linda and Kröger, Nicolaus and Chiusolo, Patrizia and Schroeder, Thomas and Robin, Marie and Gambella, Massimiliano and Blaise, Didier and Sengeloev, Henrik and Passweg, Jakob and Stelljes, Mattias and Zeiser, Robert and Yakoub-Agha, Ibrahim and Clark, Andrew and Salmenniemi, Urpu and Galieni, Piero and Rabisch, Werner and Raj, Kavita and Drozd-Sokolowska, Joanna and Battipaglia, Giorgia and Polverelli, Nicola and Czerw, Tomasz and McLornan, Donal P},
  title = {Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.70049}
}
Kostenlos starten →